PMID-sentid Pub_year Sent_text comp_official_name comp_offsetprotein_name organism prot_offset 8424425-6 1993 Ranitidine 300 mg bid provides an alternative therapeutic approach for patient populations at risk for ulcer complications. Ranitidine 0-10 BH3 interacting domain death agonist Homo sapiens 18-21 9113805-7 1997 The percentage of patients with endoscopic relapse (grade 2) after 48 weeks were 60%, 37% and 27% for placebo, ranitidine 150 mg bid and ranitidine 300 mg bid, respectively (P = 0.002 for ranitidine 150 mg bid versus placebo; P < 0.001 for ranitidine 300 mg bid versus placebo). Ranitidine 137-147 BH3 interacting domain death agonist Homo sapiens 155-158 8317406-7 1993 In a group of 34 patients studied prospectively, high dosage (300 mg orally bid) therapy with the H2-antagonist ranitidine for 8 wk significantly improved symptoms and endoscopic appearance (p < 0.05). Ranitidine 112-122 BH3 interacting domain death agonist Homo sapiens 76-79 8364260-10 1993 CONCLUSIONS: This study shows that treatment with ranitidine, in a dose up to 300 mg bid, has no significant effect on serum ethanol concentrations, even when ethanol was given in divided doses to simulate normal patterns of social drinking. Ranitidine 50-60 BH3 interacting domain death agonist Homo sapiens 85-88 28991940-8 2017 The physician prescribed ranitidine 150 mg bid for the epigastric burning and explained, once more, the significance of the STD test results. Ranitidine 25-35 BH3 interacting domain death agonist Homo sapiens 43-46 9113805-5 1997 RESULTS: Both ranitidine regimens were significantly more effective than placebo in preventing endoscopic and symptomatic relapse of reflux esphagitis (p = 0.003 for ranitidine 150 mg bid; P < 0.001 for ranitidine 300 mg bid). Ranitidine 14-24 BH3 interacting domain death agonist Homo sapiens 224-227 9113805-7 1997 The percentage of patients with endoscopic relapse (grade 2) after 48 weeks were 60%, 37% and 27% for placebo, ranitidine 150 mg bid and ranitidine 300 mg bid, respectively (P = 0.002 for ranitidine 150 mg bid versus placebo; P < 0.001 for ranitidine 300 mg bid versus placebo). Ranitidine 137-147 BH3 interacting domain death agonist Homo sapiens 155-158 9113805-7 1997 The percentage of patients with endoscopic relapse (grade 2) after 48 weeks were 60%, 37% and 27% for placebo, ranitidine 150 mg bid and ranitidine 300 mg bid, respectively (P = 0.002 for ranitidine 150 mg bid versus placebo; P < 0.001 for ranitidine 300 mg bid versus placebo). Ranitidine 137-147 BH3 interacting domain death agonist Homo sapiens 155-158 9113805-7 1997 The percentage of patients with endoscopic relapse (grade 2) after 48 weeks were 60%, 37% and 27% for placebo, ranitidine 150 mg bid and ranitidine 300 mg bid, respectively (P = 0.002 for ranitidine 150 mg bid versus placebo; P < 0.001 for ranitidine 300 mg bid versus placebo). Ranitidine 137-147 BH3 interacting domain death agonist Homo sapiens 155-158 9113805-7 1997 The percentage of patients with endoscopic relapse (grade 2) after 48 weeks were 60%, 37% and 27% for placebo, ranitidine 150 mg bid and ranitidine 300 mg bid, respectively (P = 0.002 for ranitidine 150 mg bid versus placebo; P < 0.001 for ranitidine 300 mg bid versus placebo). Ranitidine 137-147 BH3 interacting domain death agonist Homo sapiens 155-158 9113805-7 1997 The percentage of patients with endoscopic relapse (grade 2) after 48 weeks were 60%, 37% and 27% for placebo, ranitidine 150 mg bid and ranitidine 300 mg bid, respectively (P = 0.002 for ranitidine 150 mg bid versus placebo; P < 0.001 for ranitidine 300 mg bid versus placebo). Ranitidine 137-147 BH3 interacting domain death agonist Homo sapiens 155-158 9113805-7 1997 The percentage of patients with endoscopic relapse (grade 2) after 48 weeks were 60%, 37% and 27% for placebo, ranitidine 150 mg bid and ranitidine 300 mg bid, respectively (P = 0.002 for ranitidine 150 mg bid versus placebo; P < 0.001 for ranitidine 300 mg bid versus placebo). Ranitidine 137-147 BH3 interacting domain death agonist Homo sapiens 155-158 9113805-7 1997 The percentage of patients with endoscopic relapse (grade 2) after 48 weeks were 60%, 37% and 27% for placebo, ranitidine 150 mg bid and ranitidine 300 mg bid, respectively (P = 0.002 for ranitidine 150 mg bid versus placebo; P < 0.001 for ranitidine 300 mg bid versus placebo). Ranitidine 137-147 BH3 interacting domain death agonist Homo sapiens 155-158 9113805-7 1997 The percentage of patients with endoscopic relapse (grade 2) after 48 weeks were 60%, 37% and 27% for placebo, ranitidine 150 mg bid and ranitidine 300 mg bid, respectively (P = 0.002 for ranitidine 150 mg bid versus placebo; P < 0.001 for ranitidine 300 mg bid versus placebo). Ranitidine 137-147 BH3 interacting domain death agonist Homo sapiens 155-158 9113805-9 1997 CONCLUSIONS: Ranitidine 150 mg bid and 300 mg bid are safe and effective treatments in the prevention of reflux esophagitis relapse. Ranitidine 13-23 BH3 interacting domain death agonist Homo sapiens 31-34 9001831-1 1996 Ranitidine 150 mg twice daily (BID) is an approved therapeutic approach for relieving the symptoms of gastroesophageal reflux disease. Ranitidine 0-10 BH3 interacting domain death agonist Homo sapiens 31-34 3243180-3 1988 We recently observed a 66-year-old man whose steady-state serum phenytoin concentration increased 40 percent during one month after the addition to his regimen of ranitidine 150 mg bid. Ranitidine 163-173 BH3 interacting domain death agonist Homo sapiens 181-184 8016577-7 1993 In a study in 30 H. pylori-negative patients with functional dyspepsia ranitidine (150 mg bid) significantly reduced the severity of heartburn. Ranitidine 71-81 BH3 interacting domain death agonist Homo sapiens 90-93 1481550-8 1992 The corresponding values in the piroxicam/ranitidine 150 mg bid group (group B) were 3.3 +/- 1.2 (stomach) (p > 0.05 vs. group A) and 1.4 +/- 0.7 (duodenum) (p < 0.05 vs. group A). Ranitidine 42-52 BH3 interacting domain death agonist Homo sapiens 60-63 1481550-9 1992 The values in the piroxicam/ranitidine 300 mg bid group (group C) averaged 1.0 +/- 0.0 (stomach) and 0.3 +/- 0.1 (duodenum) (for both p < 0.05 vs. group A). Ranitidine 28-38 BH3 interacting domain death agonist Homo sapiens 46-49 2697116-1 1989 In a randomized double-blind study the gastroduodenal tolerability of 300 mg ASS daily has been evaluated in the presence of 150 mg ranitidine bid or placebo in 20 healthy volunteers using upper GI-endoscopy. Ranitidine 132-142 BH3 interacting domain death agonist Homo sapiens 143-146 2697116-6 1989 Concomitant administration of 150 mg ranitidine bid afforded almost full protection against 300 mg ASS daily both on day 7 and day 14 (1.9 +/- 0.6 and 2.1 +/- 0.8, respectively) (p less than 0.05). Ranitidine 37-47 BH3 interacting domain death agonist Homo sapiens 48-51 2697116-7 1989 Our data suggest that coadministration of ranitidine 150 mg bid reduces almost completely gastroduodenal lesions evoked by acetylsalicylic acid 300 mg daily. Ranitidine 42-52 BH3 interacting domain death agonist Homo sapiens 60-63 8429117-5 1993 In these time windows also the time spent above 3.0 pH units was significantly shorter for the former regimen than for 300 mg bid of both nizatidine (P < .01) and ranitidine (P < .05). Ranitidine 166-176 BH3 interacting domain death agonist Homo sapiens 126-129 1765356-0 1991 Omeprazole 20 mg uid and ranitidine 150 mg bid in the treatment of benign gastric ulcer. Ranitidine 25-35 BH3 interacting domain death agonist Homo sapiens 43-46 2241595-1 1990 This prospective multicentric randomized open trial was designed to evaluate the efficacy of ranitidine 150 mg bid vs 300 mg nocte in the short-term (4 weeks) treatment of duodenal ulcer in 15 Brazilian centers. Ranitidine 93-103 BH3 interacting domain death agonist Homo sapiens 111-114 2878726-5 1986 Treatment with 35 micrograms of enprostil BID plus 300 mg of ranitidine BID for two and 11 weeks was associated with an increased number of duodenal G-cells, a decrease in antral D-cells, and a decrease in the number of antral serotonin-containing cells. Ranitidine 61-71 BH3 interacting domain death agonist Homo sapiens 72-75 6301262-1 1983 A multicenter trial of oral ranitidine 150 mg bid was conducted in 41 patients with duodenal and 30 with gastric ulcers. Ranitidine 28-38 BH3 interacting domain death agonist Homo sapiens 46-49